Finance

Lists
OBIO:NASDAQ
Orchestra Biomed Holdings Inc
5,64 US$
-1,40%
(-0,080) 1D
5,64 US$
0,00% (0,00)
After hours
Closed: 14 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OBIO...
Open
5,70 US$
High
5,86 US$
Low
5,60 US$
Mkt. cap
338,99 მლნ.
Avg. vol.
339,62 ათ.
Volume
222,88 ათ.
52-wk high
6,50 US$
52-wk low
3,26 US$
EPS
-1,01 US$
Beta
0,52
Shares outstanding
60,10 მლნ.
No. of employees
86
Open
5,70 US$
High
5,86 US$
Low
5,60 US$
Mkt. cap
338,99 მლნ.
Avg. vol.
339,62 ათ.
Volume
222,88 ათ.
52-wk high
6,50 US$
52-wk low
3,26 US$
EPS
-1,01 US$
Beta
0,52
Shares outstanding
60,10 მლნ.
No. of employees
86
News stories
From web sources and news partners
The Daily News | Texas' Oldest Newspaper
The Daily News | Texas' Oldest Newspaper
·
1 საათის წინ
FILE PHOTO: SK Hynix at the Nasdaq market in New York
Simply Wall Street
Simply Wall Street
·
30 წუთის წინ
Raised Guidance Could Change The Case For Nextpower Stock
Bloomberg.com
Bloomberg.com
·
6 საათის წინ
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
About Orchestra Biomed Holdings Inc
CEO-
Employees86
Founded2018
Headquarters-
SectorMedical device
Analyst ratings
Based on 5 analysts giving stock ratings to OBIO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OBIO in the last 3 months.
Highest
Current 5,64 US$
15,00 US$ (+165,96%)
Average
11,20 US$ (+98,58%)
Lowest
10,00 US$ (+77,30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
10,00 US$
+77,3%
10/05/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
11,00 US$
+95%
10/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
15,00 US$
+166%
09/25/2026
Marie Thibault
BTIG
Buy
Upgraded
10,00 US$
+77,3%
09/10/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
10,00 US$
+77,3%
08/11/2026
Unknown Analyst
BTIG
Hold
Maintained
-
-
07/09/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
10,00 US$
+77,3%
05/18/2026
Matt Miksic
Barclays
Buy
Reiterated
13,00 US$
+130,5%
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
20,00 US$
+254,6%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
861,00 ათ.
30,92 მლნ.
110,00 ათ.
88,00 ათ.
Cost of goods sold
49,00 ათ.
51,00 ათ.
32,00 ათ.
25,00 ათ.
Cost of revenue
49,00 ათ.
51,00 ათ.
32,00 ათ.
25,00 ათ.
Research and development expenses
14,03 მლნ.
16,82 მლნ.
15,78 მლნ.
16,59 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,10 მლნ.
7,29 მლნ.
6,37 მლნ.
5,83 მლნ.
Operating expense
21,12 მლნ.
24,11 მლნ.
22,15 მლნ.
22,42 მლნ.
Total operating expenses
21,17 მლნ.
24,16 მლნ.
22,19 მლნ.
22,44 მლნ.
Operating income
-20,31 მლნ.
6,75 მლნ.
-22,08 მლნ.
-22,36 მლნ.
Other non operating income
-
254,00 ათ.
-376,00 ათ.
-517,00 ათ.
EBT including unusual items
-20,83 მლნ.
6,24 მლნ.
-20,69 მლნ.
-23,76 მლნ.
EBT excluding unusual items
-20,83 მლნ.
6,24 მლნ.
-22,93 მლნ.
-23,80 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,83 მლნ.
6,24 მლნ.
-20,69 მლნ.
-23,76 მლნ.
Net profit margin
-2 419,05%
20,20%
-18 810,00%
-26 994,32%
Earnings per share
-0,40
0,26
-0,33
-0,37
Interest and investment income
-
752,00 ათ.
-
-
Interest expense
-515,00 ათ.
-1,52 მლნ.
-480,00 ათ.
-927,00 ათ.
Net interest expenses
-515,00 ათ.
-763,00 ათ.
-480,00 ათ.
-927,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,23 მლნ.
6,84 მლნ.
-21,99 მლნ.
-22,26 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები